F-18 VMAT2 Tracer Precursor With Aromatic-Ring Labeling

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current F-18-AV-133 positron diagnostic agents produce metabolites like F-18-propanol, leading to slow clearance and organ background interference due to structural instability, and require complex synthesis steps and high costs.

Innovation Solution

An F-18 positron diagnostic contrast agent precursor is developed with F-18 marked on the aromatic ring, avoiding metabolites like F-18-propanol, and produced through a method involving specific chemical reactions to introduce fluorine-18 onto a pinacolborane group.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If F-18 is ligated on the side chain of AV-133, then the diagnostic agent can be synthesized, but it produces metabolites like F-18-propanol that cause slow clearance and organ background interference

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidorgan background interference

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts the problematic side chain structure from the AV-133 molecule and replaces it with a direct F-18 labeling on the core structure. This removes the source of metabolite formation (the side chain) while retaining the essential VMAT2 binding capability, thereby eliminating F-18-propanol production and the associated background interference.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the chemical structure parameter by moving the F-18 labeling position from the side chain to the core aromatic ring structure. This structural parameter change fundamentally alters the metabolic pathway, preventing dealkylation and the formation of interfering metabolites while maintaining diagnostic functionality.

Inventive Principle:

Principle #35Parameter changes

2Ease of manufacture

If F-18 anion is used for direct nucleophilic substitution on the benzene ring, then F-18 can be introduced, but higher temperature conditions and electron-withdrawing groups are required, increasing synthesis complexity

Engineering Contradiction:

Improvesynthesis simplicityVSAvoidsynthesis steps

Core Design Contradiction:

Ease of manufactureVSDevice complexity

Solution Approach 1:

The patent introduces a boronic acid ester intermediate that facilitates F-18 incorporation without requiring harsh conditions. This intermediary structure enables mild radiolabeling conditions, avoiding the need for high temperatures and subsequent removal of electron-withdrawing groups, thereby simplifying the overall synthesis process.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent performs preliminary functional group installation (boronic acid ester) before F-18 labeling, which prepares the molecule for mild radiolabeling conditions. This preliminary action enables the use of gentler reaction conditions and eliminates the need for subsequent functional group removal steps.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12551579B2F-18 positron diagnostic contrast agent precursor and method of manufacturing the same

Publication Date: 2026.02.17 ATOMIC ENERGY COUNCIL INSTITUTE OF NUCLEAR ENERGY RESEARCH

AI summary

A F-18 positron diagnostic contrast agent precursor, the F-18 positron diagnostic contrast agent prepared using the F-18 positron diagnostic contrast agent precursor can be used for positron emission tomography to detect type II vesicular monoamine transporter, produce no metabolites similar to F-18-propanol because the F-18 is marked on the aromatic ring, and can reduce the background value of normal organs while using.